Olympus increases endoscopy sales, monitors supply chain issues

The Covid-19 pandemic challenges are easing up for Olympus, but the company still predicts uncertain supply chains, higher costs and trading challenges between the US and China. Still, endoscopy sales have gone well at the Japanese medtech giant.

Photo: Yuriko Nakao/Reuters/Ritzau Scanpix

Japanese Olympus has added 22 percent to its revenue in the first nine months of the financial year, as reported in the medtech company’s third quarter figures.

Endoscopy sales in particular have contributed to the growth. The business leg grew by 20 percent in the year’s first three quarters, bringing the year-to-date sales to JPY 333.7bn (USD 2.9bn).

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs